In Stock, Ready to Ship!
Price range: $140.00 through $240.00 — or subscribe and save 20%
99% Pure | USA Made | Multi DoseSurvodutide Peptide is a dual-agonist research compound designed to activate GLP-1 and glucagon receptors, making it a strong candidate for studies focused on metabolic regulation, appetite signaling, and energy-expenditure pathways. Researchers are exploring Survodutide for its unique two-pathway profile that differs from single-target GLP molecules. For research use only.
Peptides are not ready to use. Must purchase BAC water for reconstitution.
Offers broader metabolic modulation than single agonist compounds.
May decrease caloric intake by enhancing satiety pathways in the brain.
Studied in NAFLD/NASH research for its hepatic lipid-reducing properties.
Demonstrates body fat reduction in clinical research models.
Promising for glucose uptake and insulin-related pathways.
Through glucagon activation, may increase thermogenesis and resting energy use.
Survodutide is a novel dual agonist peptide under extensive scientific investigation for its effects on weight modulation and metabolic health. It functions by targeting both GLP-1 (glucagon-like peptide-1) and glucagon receptors, making it a next-generation compound in the GLP class of research peptides. Originally developed by Boehringer Ingelheim, Survodutide represents a hybrid molecule aiming to harness the benefits of incretin-based therapies and glucagon signaling to achieve superior metabolic outcomes.
In preclinical and early clinical studies, Survodutide has shown potential in reducing body weight, improving glucose regulation, and decreasing hepatic fat content. These mechanisms are similar to those of Tirzepatide, but with unique activity in fat oxidation and hepatic lipid metabolism.
Survodutide is gaining attention as a potent research compound in the realm of obesity, insulin resistance, and non-alcoholic fatty liver disease (NAFLD). Here are several reasons why scientists are incorporating Survodutide into their experimental protocols:
Survodutide differs from other GLP-1 class peptides by leveraging glucagon receptor activation to drive additional metabolic benefits. This dual-agonist mechanism introduces a more dynamic approach to energy regulation. Unlike Semaglutide or Tirzepatide, Survodutide offers:
In side-by-side comparison (Survodutide vs Tirzepatide), researchers are finding unique advantages in hepatic parameters, and Survodutide’s ability to elevate resting energy expenditure may complement other GLP analogues.
Real Peptides offers high-purity, U.S.-made Survodutide peptide with third-party testing and transparent lab reports included on every product page.
Cartalax is a short-chain peptide studied for cartilage regeneration and gene modulation in joint tissue.
It’s primarily explored for connective tissue health, cartilage repair, and inflammatory modulation.
Yes, it is a next-generation peptide currently in clinical trials and has not yet received FDA approval outside of clinical settings.
Studies investigate Survodutide for obesity, NAFLD, NASH, insulin resistance, and weight management.
Researchers explore its effects on appetite suppression, glucose control, hepatic lipid reduction, and energy expenditure.
Both target GLP-1 and GIP/glucagon pathways, but Survodutide shows unique effects on liver fat and energy use.
Real Peptides offers U.S.-made Survodutide for research with full lab reports and high purity.
Survodutide dosage depends on the research model; consult peer-reviewed studies for guidance.
Yes. Popular research stacks include Survodutide with Cagrilintide or SLU-PP-332 for appetite and thermogenesis.
Research suggests appetite suppression, liver fat reduction, improved glucose metabolism, and thermogenic activation.
Related GLP-1 agonists include Tirzepatide, Semaglutide, and Mazdutide.
It binds to GLP-1 and glucagon receptors, promoting insulin secretion, satiety, and energy expenditure.
Typically administered subcutaneously in preclinical studies.
99% purity, third-party tested with full lab transparency on product pages.
Don't hestitate to contact us
End of Content.
